FEED ENvue Medical (FEED) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001326706
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter
What the filings say about FEED
Insiders, 180 days
-$144.9K net sold
1 seller · 0% of sales under a 10b5-1 plan
ENvue Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ENvue Medical, Inc. insiders sold a net $144.9K of stock across 18 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 14, 2026.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Glibert Christian Michael sold about $144.9K of FEED on Jun 22, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 232,920 shares held after it.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BANK OF AMERICA CORP /DE/ sold about $152 of FEED on Feb 2, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 232,820 shares held after it.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BANK OF AMERICA CORP /DE/ sold about $305 of FEED on Feb 2, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 232,387 shares held after it.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BANK OF AMERICA CORP /DE/ sold about $558 of FEED on Feb 2, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 232,385 shares held after it.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BANK OF AMERICA CORP /DE/ sold about $6 of FEED on Feb 2, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$144.9K over 180 days
more than 50% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 92% of Medical Devices
Revenue
-0.2% year over year
below 78% of Medical Devices
Margin
-712.3% net margin
below 95% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.7% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 80% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FEED
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-95.8%12M
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FEED: institutional holders (13F)
13F holdings, latest reported quarter
37,635 sh
$19.4K
15,466 sh
$8.0K
10,279 sh
$5.3K
10,000 sh
$5.2K
4,781 sh
$2.5K
Congress trades in FEED
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Glibert Christian Michael
Activist 13D · 2026-02-11
22.0%
FEED planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FEED mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$13.4K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$1.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$97 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Brian Murphy
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$424.0K
$424.0K
$306.2K
-49%
n/a
2023
$541.9K
$309.8K
$361.7K
-73%
n/a
2022
$408.8K
$110.3K
$298.6K
-64%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $144.9K sold by insiders over 180 days, 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FEED financials
Revenue growth
-0.2%
XBRL, annual
Net margin
-712.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FEED
| FY Dec 2025 | $2.6M |
| FY Dec 2024 | $2.6M |
| FY Dec 2023 | $2.3M |
| FY Dec 2022 | $752.0K |
| FY Dec 2021 | $1.7M |
| Jun 2026 | $239.0K |
| Mar 2026 | $653.0K |
| Dec 2025 | $312.0K |
| Sep 2025 | $722.0K |
| Jun 2025 | $494.0K |
| Mar 2025 | $1.0M |
| Dec 2024 | $444.0K |
| Sep 2024 | $376.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-1,094%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FEED
| FY Dec 2025 | -712.3% |
| FY Dec 2024 | -144.8% |
| FY Dec 2023 | -162.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -842.6% |
| Jun 2026 | n/a |
| Mar 2026 | -585.3% |
| Dec 2025 | -4,119% |
| Sep 2025 | +70.6% |
| Jun 2025 | -803.8% |
| Mar 2025 | -182.6% |
| Dec 2024 | -322.3% |
| Sep 2024 | -265.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$11.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FEED
| FY Dec 2025 | -$9.4M |
| FY Dec 2024 | -$2.5M |
| FY Dec 2023 | -$3.6M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -$4.4M |
| Jun 2026 | -$2.7M |
| Mar 2026 | -$4.3M |
| Dec 2025 | -$2.7M |
| Sep 2025 | -$2.0M |
| Jun 2025 | -$3.4M |
| Mar 2025 | -$1.3M |
| Dec 2024 | -$548.0K |
| Sep 2024 | -$836.0K |
At each fiscal year end
Single quarter
Debt to equity
0.04x
long-term debt only, 2025-03-31 (15 months older than the period end); equity 2026-06-30
Debt to equity FEED
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.04x |
| Mar 2026 | 0.04x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.04x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-9.28x
TTM operating cash flow over long-term debt only, 2025-03-31 (15 months older than the period end)
Cash flow to debt FEED
| FY Dec 2025 | -7.47x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -9.28x |
| Mar 2026 | -9.83x |
| Dec 2025 | -7.47x |
| Sep 2025 | -5.77x |
| Jun 2025 | -4.87x |
| Mar 2025 | -2.61x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-59.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FEED
| FY Dec 2025 | -106.6% |
| FY Dec 2024 | -160.5% |
| FY Dec 2023 | -102.8% |
| FY Dec 2022 | -114.1% |
| FY Dec 2021 | -328.1% |
| Jun 2026 | -59.1% |
| Mar 2026 | -59.5% |
| Dec 2025 | -106.6% |
| Sep 2025 | -30.5% |
| Jun 2025 | -38.2% |
| Mar 2025 | -25.5% |
| Dec 2024 | -160.5% |
| Sep 2024 | -94.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-46.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FEED
| FY Dec 2025 | -81.3% |
| FY Dec 2024 | -71.9% |
| FY Dec 2023 | -59.1% |
| FY Dec 2022 | -75.1% |
| FY Dec 2021 | -169.5% |
| Jun 2026 | -46.9% |
| Mar 2026 | -48.0% |
| Dec 2025 | -81.3% |
| Sep 2025 | -22.9% |
| Jun 2025 | -28.9% |
| Mar 2025 | -19.8% |
| Dec 2024 | -71.9% |
| Sep 2024 | -51.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital FEED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-69.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FEED
| FY Dec 2025 | -129.4% |
| FY Dec 2024 | -139.7% |
| FY Dec 2023 | -88.3% |
| FY Dec 2022 | -97.5% |
| FY Dec 2021 | -94.4% |
| Jun 2026 | -69.0% |
| Mar 2026 | -71.8% |
| Dec 2025 | -129.4% |
| Sep 2025 | -42.1% |
| Jun 2025 | -34.0% |
| Mar 2025 | -24.5% |
| Dec 2024 | -139.7% |
| Sep 2024 | -81.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FEED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.9M
market value at close 2026-10-26 on 2026-08-17 shares, plus long-term debt only, 2025-03-31 (15 months older than the period end), minus cash 2026-06-30
Enterprise value FEED
| FY Dec 2025 | -$455.5K |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $3.3M |
| Mar 2026 | $1.6M |
| Dec 2025 | -$455.5K |
| Sep 2025 | -$1.2M |
| Jun 2025 | $21.2M |
| Mar 2025 | $26.6M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-423.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield FEED
| FY Dec 2025 | -375.2% |
| FY Dec 2024 | -1.0% |
| FY Dec 2023 | -1.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -374.3% |
| Mar 2026 | -479.3% |
| Dec 2025 | -375.2% |
| Sep 2025 | -162.0% |
| Jun 2025 | -25.5% |
| Mar 2025 | -12.7% |
| Dec 2024 | -1.0% |
| Sep 2024 | -1.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FEED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.6M | $2.6M | $2.3M | $752.0K |
| Gross profit | $153.0K | $1.5M | $1.5M | $167.0K |
| Operating income | -$22.9M | -$3.6M | -$3.4M | -$5.0M |
| Net income | -$18.2M | -$3.7M | -$3.7M | -$5.4M |
| EPS (diluted) | -26.69 | -137.30 | -23.32 | -3.84 |
| Operating cash flow | -$9.4M | -$2.5M | -$3.6M | -$7.0M |
| Cash | $4.2M | $752.0K | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
FEED Stock Sonar score 6/7 axes
Find similar shapesCompareFEED ranks highest on risk and compliance (46th percentile) and financial health (45th), and lowest on institutional and government (8th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FEED filings, in plain words
Are ENvue Medical insiders buying or selling FEED?
In the 180 days to 2026-10-28, ENvue Medical insiders were net sellers, a net $144.9K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, ENvue Medical insiders were net sellers of FEED, a net $144.9K across purchases and sales reported on Form 4 by 1 seller. The latest 5% ownership filing is a 13D by Glibert Christian Michael, filed 2026-02-11, for 22.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
